HOMOLOGY MEDICINES INC (FIXX) Fundamental Analysis & Valuation

NASDAQ:FIXX • US4380831077

Current stock price

0.9347 USD
+0.01 (+0.77%)
At close:
0.892 USD
-0.04 (-4.57%)
After Hours:

This FIXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. FIXX Profitability Analysis

1.1 Basic Checks

  • FIXX had negative earnings in the past year.
  • FIXX had a negative operating cash flow in the past year.
  • In the past 5 years FIXX always reported negative net income.
  • FIXX had a negative operating cash flow in each of the past 5 years.
FIXX Yearly Net Income VS EBIT VS OCF VS FCFFIXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -133.57%, FIXX is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
  • The Return On Equity of FIXX (-154.74%) is worse than 67.69% of its industry peers.
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROIC N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
FIXX Yearly ROA, ROE, ROICFIXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FIXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FIXX Yearly Profit, Operating, Gross MarginsFIXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. FIXX Health Analysis

2.1 Basic Checks

  • FIXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for FIXX has been increased compared to 1 year ago.
  • There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FIXX Yearly Shares OutstandingFIXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
FIXX Yearly Total Debt VS Total AssetsFIXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -8.72, we must say that FIXX is in the distress zone and has some risk of bankruptcy.
  • FIXX has a worse Altman-Z score (-8.72) than 75.00% of its industry peers.
  • FIXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACC9.71%
FIXX Yearly LT Debt VS Equity VS FCFFIXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

  • FIXX has a Current Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 7.25, FIXX is doing good in the industry, outperforming 69.56% of the companies in the same industry.
  • FIXX has a Quick Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of FIXX (7.25) is better than 69.56% of its industry peers.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
FIXX Yearly Current Assets VS Current LiabilitesFIXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. FIXX Growth Analysis

3.1 Past

  • The earnings per share for FIXX have decreased by -3.16% in the last year.
  • FIXX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -64.06%.
  • FIXX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -26.31% yearly.
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%

3.2 Future

  • FIXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
  • FIXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.76% yearly.
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FIXX Yearly Revenue VS EstimatesFIXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
FIXX Yearly EPS VS EstimatesFIXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. FIXX Valuation Analysis

4.1 Price/Earnings Ratio

  • FIXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FIXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FIXX Price Earnings VS Forward Price EarningsFIXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FIXX Per share dataFIXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y9.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FIXX Dividend Analysis

5.1 Amount

  • No dividends for FIXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

FIXX Fundamentals: All Metrics, Ratios and Statistics

HOMOLOGY MEDICINES INC

NASDAQ:FIXX (3/25/2024, 8:23:28 PM)

After market: 0.892 -0.04 (-4.57%)

0.9347

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-09
Inst Owners0.11%
Inst Owner Change0%
Ins Owners15.02%
Ins Owner Change0%
Market Cap54.23M
Revenue(TTM)1.15M
Net Income(TTM)-112.95M
Analysts43.33
Price Target1.53 (63.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.28%
Min EPS beat(2)-33.05%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-10.74%
Min EPS beat(4)-33.05%
Max EPS beat(4)8.5%
EPS beat(8)4
Avg EPS beat(8)-3.52%
EPS beat(12)8
Avg EPS beat(12)7.79%
EPS beat(16)10
Avg EPS beat(16)7.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.16
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.02
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.45%
Cap/Sales 19.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -8.72
F-Score2
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)56.06%
Cap/Depr(5y)112.08%
Cap/Sales(3y)22.33%
Cap/Sales(5y)302.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%
EBIT growth 1Y30.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.61%
EBIT Next 3Y32.15%
EBIT Next 5Y37.25%
FCF growth 1Y16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.34%
OCF growth 3YN/A
OCF growth 5YN/A

HOMOLOGY MEDICINES INC / FIXX Fundamental Analysis FAQ

What is the fundamental rating for FIXX stock?

ChartMill assigns a fundamental rating of 2 / 10 to FIXX.


What is the valuation status of HOMOLOGY MEDICINES INC (FIXX) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOMOLOGY MEDICINES INC (FIXX). This can be considered as Overvalued.


Can you provide the profitability details for HOMOLOGY MEDICINES INC?

HOMOLOGY MEDICINES INC (FIXX) has a profitability rating of 0 / 10.


How financially healthy is HOMOLOGY MEDICINES INC?

The financial health rating of HOMOLOGY MEDICINES INC (FIXX) is 6 / 10.


What is the earnings growth outlook for HOMOLOGY MEDICINES INC?

The Earnings per Share (EPS) of HOMOLOGY MEDICINES INC (FIXX) is expected to grow by 64.09% in the next year.